Syncom Formulations Reports Strong Financial Growth Amid Concerns Over Non-Operating Income in March 2025

Syncom Formulations (India), a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's evaluation, with a revision in its score reflecting the positive developments observed during this period. The company achieved a Profit After Tax (PAT) of Rs 17.68 crore, marking a significant growth compared to the average PAT of the previous four quarters. This trend is mirrored in the net sales, which reached Rs 148.88 crore, also showing substantial growth over the same comparative period. Operating Profit (PBDIT) and Profit Before Tax (PBT) figures have similarly reached new highs, indicating a robust operational performance. However, it is important to note that the increase in non-operating income, which stood at Rs 6.94 crore, raises questions about sustainability, as it stems from activities outside the core business operations. Overall, Syncom Formulations has demonstrated strong financial metrics in this quarter, leading to adjustments in its evaluation. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.